The Peptide Field. Tesamorelin: approval and evidence record.

Editorial review: 2026-08-01. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/tesamorelin

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=tesamorelin#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: An FDA-approved product exists for a narrow indication

Exact product limits: The two approved products are not interchangeable. Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.

Human outcomes: Strong. Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population.

Body effects in people: Strong. The approved label characterizes IGF-1 response, exposure, and product-specific use.

What the evidence shows: Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.

What remains unknown: These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.

Safety limits: This prescription drug has benefits for a specific group and important monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.

Product record: Egrifta SV. Form: 2 mg single-dose vial. Route: Subcutaneous.
Scope: Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: 2024 label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf

Product record: Egrifta WR. Form: 11.6 mg single-patient-use multidose vial. Route: Subcutaneous.
Scope: Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Published label: March 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf

Approval claim: “Tesamorelin is an approved general weight-loss drug.”
Verdict: Misleading. The label specifically says it is not indicated for weight-loss management.
Evidence basis: Regulatory or product record. Scope: The current Egrifta SV and Egrifta WR labels.
Claim sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin) prescribing information. 2024. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf

U.S. Food and Drug Administration. EGRIFTA WR (tesamorelin) prescribing information. 2025. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf

PubMed · Journal of Acquired Immune Deficiency Syndromes. Tesamorelin in HIV-associated abdominal fat accumulation. 2010. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/20101189/

World Anti-Doping Agency. 2026 Prohibited List. 2026. Accessed 2026-07-23. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

Keep the limits, review date, and sources with this record. Check the current source for changes.